3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Breast
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
Temozolomide
33
Radiotherapy
32
pembrolizumab
18
Cyclophosphamide
18
Irinotecan
16
Gemcitabine
16
Doxorubicin
16
Nivolumab
11
Docetaxel
11
Sirolimus
10
Imatinib Mesylate
10
Ifosfamide
10
Filgrastim
10
Radiation
9
Bevacizumab
9
Vincristine
8
Carboplatin
8
pazopanib
7
Everolimus
7
temsirolimus
6
atezolizumab
6
Peripheral Blood Stem Cell Transplantation
6
Etoposide
6
fludarabine phosphate
5
Vorinostat
5
Specimen Handling
5
Radiotherapy, Conformal
5
PM 01183
5
Ipilimumab
5
Erlotinib Hydrochloride
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colony-Stimulating Factors
×
Sarcoma
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled